| Document |
Document Title |
|
WO/2019/115577A1 |
The present application relates to a specific fluorene derivative, to its use in an electronic device and to an electronic device comprising said fluorene derivatives. Further, the present application relates to a process for the prepara...
|
|
WO/2019/115781A1 |
The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit t...
|
|
WO/2019/110427A1 |
Compounds of the formula (I) wherein the subsitiuents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and t...
|
|
WO/2018/151861A9 |
Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, pr...
|
|
WO/2019/110137A1 |
The present invention relates to o-phenoxy and o-benzyloxypropylamino derivatives (I) having pharmacological activity towards the α2δ subunit, in particular the a2S-1 subunit, of the voltage-gated calcium channel, to processes of prepa...
|
|
WO/2019/109458A1 |
Disclosed are an organic monomolecular white light material, a preparation method therefor, and an OLED device. The organic monomolecular white light material has room temperature phosphorescence emission properties in a solid state, and...
|
|
WO/2019/107394A1 |
The present invention addresses the problem of providing a liquid crystal compound that satisfies at least one physical property including a low minimum temperature for the liquid crystal phase, a low viscosity, a suitable optical anisot...
|
|
WO/2019/105234A1 |
The present invention relates to an aromatic compound, a pharmaceutical composition comprising the compound, and a method for preparing the compound and an intermediate thereof. The present invention further relates to use of the compoun...
|
|
WO/2019/108800A1 |
The invention relates to compounds that promote hematopoietic regeneration. The invention further relates to methods of promoting hematopoietic regeneration using the novel compounds of the invention.
|
|
WO/2019/106029A1 |
The present invention relates to norbornadiene compounds (Formula I), and the corresponding quadricyclane compounds (Formula III). The compounds are to be included in a molecular thermal systems (MOST), and to be used for storing solar e...
|
|
WO/2019/102054A1 |
Non-glycosidic analogues of alpha-galactosylceramide of formula (I), wherein A, Z, Ra, Rb and Rc have the meaning indicated in the description, as NKT cell activators.
|
|
WO/2019/098796A1 |
The present specification provides a compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2019/098773A1 |
The present specification provides a compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2019/087548A1 |
Provided is a fluorine-containing ether compound which is capable of forming a lubricating layer that has excellent wear resistance even if the thickness thereof is thin, and which is suitable as a material for a lubricant for magnetic r...
|
|
WO/2019/086707A1 |
The present invention relates to a method of reducing the number or percentage of pluripotent stem cells or of enriching differentiating or differentiated cells in a cell population comprising pluripotent stem cells and differentiating c...
|
|
WO/2019/087028A1 |
Provided are IDO1 inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
|
|
WO/2019/087129A1 |
The invention relates to compounds of formula I and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/ma...
|
|
WO/2019/080882A1 |
Disclosed are a compound as shown in formula (I), a pharmaceutical composition comprising the compound of formula (I), and the use of the compound and pharmaceutical composition in the preparation of an HDAC inhibitor drug. The compound ...
|
|
WO/2019/083215A1 |
The present invention relates to a novel compound and an organic electroluminescent device comprising same. The compound, according to the present invention, is used for an organic layer, preferably, a light-emitting layer, of an organic...
|
|
WO/2019/081346A1 |
A process for preparing the benzothiophen-2-yl boronate of formula (VI) which serves as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of proliferative disorders, such as ...
|
|
WO/2019/076709A1 |
The present invention provides compounds of formulae (1) (2) wherein R1and R2are C1-30alkyl, C2-3O-alkenyl, C2-30-alkynyl, C5-7-cycloalkyl, C6-14-aryl or 5 to 14 membered heteroaryl, wherein C1-30-alkyl, C2-3O-alkenyl and C2-3O-alkynyl c...
|
|
WO/2019/077106A1 |
The present invention relates to new compounds of general formula (I) showing great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channel...
|
|
WO/2019/076343A1 |
Disclosed are a PD-1/PD-L1 small-molecule inhibitor and a preparation method therefor and use thereof. In particular, disclosed are a compound which has a structure as shown in formula L, a stereoisomer or a tautomer thereof, or a pharma...
|
|
WO/2019/076904A1 |
The application relates to compounds of formula (I) that show great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activi...
|
|
WO/2019/076852A1 |
The present invention relates to dibenzofuans and dibenzothiophenes thiophenesof formula (l) in which the occurring groups and parameters have the meanings as indicated in claim 1, to liquid-crystalline media comprising same and to high-...
|
|
WO/2019/078246A1 |
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is useful as an IDO/TDO inhibitor. The compound represented by formula (I) or a pharmaceutically acceptable salt thereof can, for exam...
|
|
WO/2019/061299A1 |
Provided is a one-step amination reaction for producing an aminomethyl substituted heterocycloalkane, notably (tetrahydrofuran-2, 5-diyl) dimethanamine.
|
|
WO/2019/067180A1 |
This disclosure provides a family of compounds that absorb and fluoresce in the short wave infrared region (SWIR, optionally 1000 nm to 1300 run), including hydrophilic compounds that exhibit absorption and emission spectral profiles in ...
|
|
WO/2019/066250A1 |
The present invention provides: a compound represented by chemical formula 1 or chemical formula A; an organic electronic element comprising a first electrode, a second electrode, and an organic layer between the first electrode and the ...
|
|
WO/2019/066242A1 |
Disclosed are: a compound represented by chemical formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode; and an electronic dev...
|
|
WO/2019/057196A1 |
Fluorescent compounds that have aggregation-induced emission (AIE) characteristics and exhibit near infrared absorption. The compounds can be synthesized using a one-pot synthetic approach. The compounds can be utilized as LD-specific bi...
|
|
WO/2019/057969A1 |
The present invention relates to small molecule compounds and their use as agonists of farnesoid X receptor (FXR) and/or peroxisome proliferator activated receptor delta (PPARδ). The present invention also relates to the use of said com...
|
|
WO/2019/053090A1 |
The present disclosure provides a compound of formula (I): (I); or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treatin...
|
|
WO/2019/052236A1 |
The present invention pertains to the field of fine chemicals and related chemical technologies and provides a preparation method for a butadiene derivative. Phenylacetylene and derivatives thereof are used as raw materials and react in ...
|
|
WO/2019/054148A1 |
A fluorine-containing ether compound which is represented by R1-R2-CH2-R3-CH2-R4-R5. (In the formula, R3 represents a perfluoropolyether chain; each of R1 and R5 independently represents an optionally substituted alkyl group, an organic ...
|
|
WO/2019/052980A1 |
The present invention relates to a compound of formula (I) as defined in the description and in the claims. The compound of formula (I) can be used in the manufacture of medicaments.
|
|
WO/2019/046931A1 |
Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions invol...
|
|
WO/2019/048458A1 |
The present application relates to compounds of formulas (I) and (II), to methods for the production thereof, and to the use thereof in electronic devices.
|
|
WO/2019/048443A1 |
The present application relates to compounds of formula (I), to methods for the producing thereof, and to the use thereof in electronic devices.
|
|
WO/2018/139767A9 |
The present invention provides a novel amine-based compound and an organic light emitting device using the same.
|
|
WO/2019/043060A1 |
The present invention relates to binaphthyl compounds of the formula (I), which are suitable as monomers for preparing polycarbonate resins having beneficial optical properties and which can be used for producing optical lenses: Formula ...
|
|
WO/2019/043642A1 |
The present invention relates to novel thiophene compounds of general Formula I, and their stereoisomers (diastereoisomers, enantiomers), pure or mixed, racemic mixtures, geometrical isomers, tautomers, pharmaceutically acceptable salts,...
|
|
WO/2019/039290A1 |
Provided are: an actinic ray-sensitive or radiation-sensitive resin composition that has excellent resolution, exposure latitude, and pattern shape properties; and a resist film, a pattern-forming method, a method for producing an electr...
|
|
WO/2019/039200A1 |
Provided is a fluorinated ether compound, which can be used advantageously as a lubricant material for a magnetic recording medium, the lubricant material being capable of forming a lubricant layer having excellent chemical resistance an...
|
|
WO/2019/039265A1 |
A fluorine-containing ether compound characterized by being represented by formula (1). R1–R2–CH2–R3–CH2–R4–R5 (1) (In formula (1), R3 indicates a perfluoropolyether chain. R2 and R4 indicate a divalent linking group having a...
|
|
WO/2019/035453A1 |
Provided is a catalyst represented by general formula (1). In general formula (1), R1-R14 each independently represent a hydrogen atom or a substituent.
|
|
WO/2019/036678A1 |
Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
|
|
WO/2019/033799A1 |
Disclosed is a compound, with the structure formula thereof being as shown in formula (I) below. The compound disclosed by the present invention can be used as a liquid crystal compound, and at the same time, same also overcomes the prob...
|
|
WO/2019/036624A1 |
In various embodiments, provided herein are pamoate salts of monoamine Anti-Parkinsons disease agents including rotigotine, ropinirole, pramipexole, selegiline, rasagiline, and safinamide, pharmaceutical composition comprising the same, ...
|
|
WO/2019/036374A1 |
Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula (I). The compounds are useful for treating inflammatory and autoimmune diseases.
|
